About this course
Given the increasing burden of dengue worldwide and limitations to vector control strategies, live-attenuated vaccines are key for dengue prevention. In this e-Learning module, Dr Karen Nadua discusses the burden of dengue, current control measures and associated challenges, and the latest evidence for live-attenuated dengue vaccines in development or licensed. Dr Nadua is a Pediatric Infectious Disease Specialist at KK Women’s and Children’s Hospital and a Clinical Assistant Professor at SingHealth Duke-NUS Academic Medical Centre for the Pediatrics Academic Clinical Programme.
Upon completing this module, participants will be able to:
- Describe the burden of dengue, especially pertaining to pediatric populations across Asia
- Understand the limitations of vector control strategies
- Distinguish the three key live-attenuated dengue vaccines in development or licensed
- Dengue burden
- Vector control and its limitations
- Available efficacy, immunogenicity and safety data for CYD-TDV, TAK-003 and Butantan-DV
1 CME Point Available
- Score at least 80% in the multiple-choice quiz.
- A certificate can be downloaded upon successful completion. Please use the information on the certificate to claim your CME points.